Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech ...
BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...
Has Applied Therapeutics Inc. (APLT) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Applied Therapeutics Inc. is one of 1022 ...
AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...
Oppenheimer analyst Jay Olson maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $15.85.
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) and keeping the price target at $57.00. Terence Flynn’s rating is based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback